Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea’s largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex’s FlexFactory(R) biomanufacturing platform.
The companies expect to define specific terms of the alliance in the coming months.
“The alliance with Xcellerex is part of our strategic initiative to expand our vaccine business in Korea and beyond,” said Mr. Chang Geun Kim, SK Chemicals Vice Chairman and CEO. “The FlexFactory platform, which allows us to rapidly, flexibly, and efficiently deploy advanced cell culture-based manufacturing capacity, will enable us to accelerate the development and commercialization of our pipeline products, including our influenza and pneumococcal conjugate vaccines.” Through its life sciences division, SK Chemicals currently manufactures, markets, and distributes a number of vaccines produced using traditional vaccine production techniques.
“The agreement with SK Chemicals, a leading industrial group in South Korea, recognizes the strength and flexibility of our FlexFactory platform to rapidly establish and scale manufacturing capacity across its vaccine pipeline,” said Guy Broadbent, Xcellerex President and CEO. “With its growing vaccine pipeline and commitment to vaccine innovation and growth, SK Chemicals is an ideal fit with Xcellerex’s FlexFactory platform and our unique business model.” Mr. Broadbent noted the company’s model allows partners to bring manufacturing capacity on line using Xcellerex’s process and manufacturing services capability during its partners’ facility construction phase and then TransPlant(TM) the FlexFactory manufacturing lines to the partner.
